NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FOR CAR T-CELL THERAPY ACROSS EUROPE Stockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) ...

– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC ...

was awarded to the King Faisal Specialist Hospital & Research Centre for revolutionising organ transplantation through ...

In a report released yesterday, Matthew Biegler from Oppenheimer maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

Shares of Gilead Sciences, Inc. (GILD) traded nearly 3% lower in pre-market on Friday after the company reported ...

Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year ...

Gilead Sciences Inc. closed 13.61% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences Inc. closed 15.47% short of its 52-week high of $119.96, which the company reached on March 10th.

Truist Financial analyst Asthika Goonewardene maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...